James Larkin, MD, PhD, medical oncologist, Royal Marsden Hospital, discusses a phase II study that examined the combination of lenvatinib and everolimus, single-agent lenvatinib, and single-agent everolimus in patients with renal cell carcinoma (RCC).

The three-arm study looked at patients who previously received sunitinib or pazopanib, Larkin explains. In patients who received everolimus, PFS was approximately 5 months, while PFS was 7 months in patients who received lenvatinib. Patients who received the combination had a median PFS of 14 months.

Toxicities associated with the combination, which included high blood pressure and diarrhea, were manageable and expected.

OncLive TV

® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers. 

Genitourinary Cancers

The OncLive Genitourinary Cancer condition center page is a comprehensive resource for clinical news and expert insights across genitourinary (GU) malignancies, including renal cell carcinoma, urothelial carcinoma, and prostate cancer. This section features news articles, interviews in written and video format, and podcasts that focus on the evolving treatment paradigm of GU cancers and emerging research. 

James Larkin, MD, PhD, medical oncologist, Royal Marsden Hospital, discusses a phase II study that examined the combination of lenvatinib and everolimus versus either agent alone in patients with renal cell carcinoma. 


Dr. Larkin on Lenvatinib Plus Everolimus in Patients With RCC